Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Phase 2 Active not recruiting 171 enrolled National Cancer Institute (NCI)

RandomizedCrossoverDouble-blindTreatment

Summary

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2013-09-20
Primary completion: 2019-03-05
Completion: 2026-09-10

Outcome

Met primary endpoint

paper Median PFS was 11.8 versus 7.6 months in pazopanib versus placebo, respectively (hazard ratio, 0.54 [95% CI, 0.37 to 0.79]; P < .001); PMID 40902132 ↗

paper CONCLUSION: Pazopanib compared with placebo significantly improves PFS in patients with progressive epNET PMID 40902132 ↗

Publications

Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). J Clin Oncol. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral